Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Apparently, It Takes Gull to Be Me
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Aug 25, 2023 8:59pm
70 Views
Post# 35606340

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Apparently, It Takes Gull to Be Me

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Apparently, It Takes Gull to Be MeTT-Boy. I think you should ask Dan Carlson of Tailwinds that question.

I'd be intersted in his answer because it's amazing to me that he gets paid as a promoter.

Go back and look at the buying he brought in after he was hired by Bioasis.

This much - right===>>>     <<<===here.

I understand why he has a hate on for Bioasis and me. He's embarrassed himself. Did you see the hits my post got when I put the SEO tags in there? I think it got 5 or 6 hundred hits. 

He wouldn't have attracted all that attention if it wasn't for you. You kept putting his post on top. I meant to thank you for that. (Did he ask you to stop?)

jd



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities